[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Will Enanta's Hepatitis Pipeline Finally Answer Whether It Has a Business Model?

Enanta Pharmaceuticals (NASDAQ:ENTA) reports fiscal third-quarter 2026 earnings on August 10, 2026, with analysts expecting continued improvement in the company's loss per share as its pipeline advances. The central question is whether the biotech can sustain its five-quarter streak of earnings beats while demonstrating progress on its protease inhibitor and kinase inhibitor programs. With the stock trading near $13.74 and analysts maintaining a bullish stance, the release will test whether operational momentum can justify the consensus price target of nearly $20.

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and liver diseases, with a pipeline that...

Fundamentals

See More
  • Market Capitalization, $K 400,404
  • Shares Outstanding, K 29,078
  • Annual Sales, $ 65,320 K
  • Annual Income, $ -81,890 K
  • EBIT $ -60 M
  • EBITDA $ -55 M
  • 60-Month Beta 0.98
  • Price/Sales 5.94
  • Price/Cash Flow N/A
  • Price/Book 3.32

Options Overview Details

View History
  • Implied Volatility 104.71% (+19.04%)
  • Historical Volatility 39.32%
  • IV Percentile 44%
  • IV Rank 23.90%
  • IV High 239.69% on 09/26/25
  • IV Low 62.31% on 05/19/26
  • Expected Move (DTE 11) 1.32 (9.58%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 72
  • Put/Call OI Ratio 1.63
  • Today's Open Interest 1,164
  • Open Int (30-Day) 1,001
  • Expected Range 12.43 to 15.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.37
  • Number of Estimates 2
  • High Estimate $-0.22
  • Low Estimate $-0.51
  • Prior Year $-0.85
  • Growth Rate Est. (year over year) +56.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.32 +12.18%
on 07/30/26
13.99 -1.22%
on 07/20/26
+0.12 (+0.88%)
since 07/10/26
3-Month
10.86 +27.26%
on 06/08/26
15.89 -13.03%
on 05/11/26
-1.52 (-9.91%)
since 05/08/26
52-Week
6.45 +114.26%
on 08/11/25
17.15 -19.42%
on 12/29/25
+6.92 (+100.29%)
since 08/08/25

Most Recent Stories

More News
Will Enanta's Hepatitis Pipeline Finally Answer Whether It Has a Business Model?

Barchart Research What to Expect from ENTA Earnings ENTA Generated August 7, 2026 Current Price $13.74 EPS Estimate $$-0.37 Consensus Rating Strong Buy Average Move 5.44% Will Enanta's Hepatitis Pipeline...

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

MAVIRET® (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection ...

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial...

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 ...

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

Phase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026...

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.82 (+0.36%)
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...

ENTA : 13.82 (+0.36%)

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

3rd Resistance Point 14.50
2nd Resistance Point 14.18
1st Resistance Point 13.98
Last Price 13.82
1st Support Level 13.46
2nd Support Level 13.14
3rd Support Level 12.94

See More

52-Week High 17.15
Last Price 13.82
Fibonacci 61.8% 13.06
Fibonacci 50% 11.80
Fibonacci 38.2% 10.54
52-Week Low 6.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.